Sanara Medtech Inc (SMTI) - Total Liabilities

Latest as of December 2025: $67.01 Million USD

Based on the latest financial reports, Sanara Medtech Inc (SMTI) has total liabilities worth $67.01 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SMTI shareholders equity momentum to track the company's year-over-year net asset growth rate.

Sanara Medtech Inc - Total Liabilities Trend (1999–2025)

This chart illustrates how Sanara Medtech Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Sanara Medtech Inc to measure how efficiently the company converts operating cash flow to free cash.

Sanara Medtech Inc Competitors by Total Liabilities

The table below lists competitors of Sanara Medtech Inc ranked by their total liabilities.

Company Country Total Liabilities
Sula Vineyards Limited
NSE:SULA
India Rs5.08 Billion
Braemar Hotel & Resorts Inc
NYSE:BHR
USA $1.35 Billion
CERENO SCIENTIFIC AB B
F:4A1
Germany €150.20 Million
Getty Images Holdings Inc.
NYSE:GETY
USA $2.63 Billion
Westwood Holdings Group Inc
NYSE:WHG
USA $24.31 Million
Petronor E&P Ltd
OL:PNOR
Norway Nkr51.78 Million
Byggma
OL:BMA
Norway Nkr2.08 Billion
China ZhengTong Auto Services Holdings Limited
F:ZA0
Germany €23.72 Billion

Liability Composition Analysis (1999–2025)

This chart breaks down Sanara Medtech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SMTI company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 11.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.92 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sanara Medtech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sanara Medtech Inc (1999–2025)

The table below shows the annual total liabilities of Sanara Medtech Inc from 1999 to 2025.

Year Total Liabilities Change
2025-12-31 $67.01 Million +36.26%
2024-12-31 $49.18 Million +67.95%
2023-12-31 $29.28 Million +51.61%
2022-12-31 $19.32 Million +209.32%
2021-12-31 $6.24 Million +56.66%
2020-12-31 $3.99 Million -15.64%
2019-12-31 $4.72 Million +144.81%
2018-12-31 $1.93 Million -8.76%
2017-12-31 $2.12 Million -18.46%
2016-12-31 $2.59 Million -2.58%
2015-12-31 $2.66 Million +14.60%
2014-12-31 $2.32 Million -32.56%
2013-12-31 $3.45 Million -33.73%
2012-12-31 $5.20 Million -32.41%
2011-12-31 $7.69 Million +96.51%
2010-12-31 $3.91 Million +59.28%
2009-12-31 $2.46 Million +419.61%
2008-12-31 $472.97K -78.69%
2007-12-31 $2.22 Million +25.59%
2006-12-31 $1.77 Million +95.22%
2005-12-31 $905.27K +458.02%
2004-12-31 $162.23K -95.44%
2001-12-31 $3.56 Million +41.53%
2000-12-31 $2.52 Million +37.64%
1999-12-31 $1.83 Million --

About Sanara Medtech Inc

NASDAQ:SMTI USA Medical Instruments & Supplies
Market Cap
$310.40 Million
Market Cap Rank
#17451 Global
#4079 in USA
Share Price
$33.86
Change (1 day)
-0.59%
52-Week Range
$16.34 - $35.75
All Time High
$52.75
About

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more